The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia

Bipolar Disorders

Volumn 17, Issue 5, 2015, Pages 528-535

  Bonaccorso, Stefania ^a   Sodhi, Monsheel ^b   Li, Jiang ^c   Bobo, William V ^d   Chen, Yuejin ^e   Tumuklu, Mevhibe ^f   Theleritis, Christos ^a   Jayathilake, Karuna ^c   Meltzer, Herbert Y ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^f GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Antipsychotic drugs; Bipolar disorder; Body mass index; Brain derived neurotrophic factor (BDNF) val66Met; Glucose; Lipids; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BDNF GENE; BIPOLAR DISORDER; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ALLELE; CHEMICALLY INDUCED; DYSLIPIDEMIA; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTOR;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; BLOOD GLUCOSE; BODY MASS INDEX; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; GENOTYPE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 84938955218     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12294     Document Type: Article

References (57)

1. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr Bull 2013; 39: 306-318.
2. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010; 126: 366-387.
3. van Winkel R, De Hert M, Van Eyck D et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348.
4. de Almeida KM, Moreira CL, Lafer B. Metabolic syndrome and bipolar disorder: what should psychiatrists know? CNS Neurosci Ther 2012; 18: 160-166.
5. Vancampfort D, Vansteelandt K, Correll CU et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170: 265-274.
6. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13 (Suppl. 7): S170-S177.
7. Meyer J, Koro CE, L'Italien GJ. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry 2005; 17: 173-180.
8. Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sci 2004; 74: 1999-2008.
9. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21: 93-98.
10. Yumru M, Savas HA, Kurt E et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98: 247-252.
11. Allison DB, Mentore JL, Heo M. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychol 1999; 156: 1686-1696.
12. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005; 27: 1930-1941.
13. Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry 2011; 72: 1602-1610.
14. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011; 95: 875-892.
15. Lebrun B, Bariohay B, Moyse E, Jean A. Brain-derived neurotrophic factor (BDNF) and food intake regulation: a mini review. Auton Neurosci 2006; 126-127: 30-38.
16. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996; 19: 289-317.
17. Vanevski F, Xu B. Molecular and neural bases underlying roles of BDNF in the control of body weight. Front Neurosci 2013; 7: 37.
18. Lyons WE, Mamounas LA, Ricaurte GA et al. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotoninergic abnormalities. Proc Natl Acad Sci USA 1999; 96: 15239-15244.
19. Coppola V, Tessarollo L. Control of hyperphagia prevents obesity in BDNF heterozygous mice. NeuroReport 2004; 15: 2665-2668.
20. Duan W, Guo Z, Jiang H, Ware M, Mattson MP. Reversal of behavioral and metabolic abnormalities, and insulin resistance syndrome, by dietary restriction in mice deficient in brain-derived neurotrophic factor. Endocrinology 2003; 144: 2446-2453.
21. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009; 41: 18-24.
22. Akkermann K, Hiio K, Villa I, Harro J. Food restrictions leads to binge eating dependent upon the effect of the brain-derived neurotrophic factor Val66Met polymorphism. Psychiatry Res 2011; 185: 39-43.
23. Day J, Ternouth A, Collier DA. Eating disorders and obesity: two sides of the same coin? Epidemiol Psichiatr Soc 2009; 18: 96-100.
24. Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X. Brain derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007; 61: 911-922.
25. Koizumi H, Hashimoto K, Itoh K et al. Association between the brain-derived neurotrophic factor 196G/A polymorphism and eating disorders. Am J Med Genet B Neuropsychiatr Genet 2004; 127B: 125-127.
26. Monteleone P, Zanardini R, Tortorella A et al. The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neurosci Lett 2006; 406: 133-137.
27. Ribases M, Gratacos M, Fernandez-Aranda F et al. Association of BDNF with anorexia, bulimia and age of onset of weight loss in six European populations. Hum Mol Genet 2004; 13: 1205-1212.
28. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011; 16: 960-972.
29. Sears C, Markie D, Olds R, Fitches A. Evidence of associations between bipolar disorder and the brain-derived neurotrophic factor (BDNF) gene. Bipolar Disord 2011; 13: 630-637.
30. Miller S, Hallmayer J, Wang PW, Hill SJ, Johnson SL, Ketter TA. Brain-derived neurotrophic factor val66met genotype and early life stress effects upon bipolar course. J Psychiatr Res 2013; 47: 252-258.
31. Zhang XY, Zhou DF, Wu GY et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008; 33: 2200-2205.
32. Zai GC, Zai CC, Chowdhury NI et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 96-101.
33. Liu G, Gould AL. Comparison of alternative strategies for analysis of longitudinal trials with dropouts. J Biopharm Stat 2002; 12: 207-226.
34. Tsai A, Liou YJ, Hong CJ, Wu CL, Tsai SJ, Bai YM. Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment. Neuromolecular Med 2011; 13: 328-333.
35. Pruunsild P, Kazantseva A, Aid T, Palm K, Timmusk T. Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 2007; 90: 397-406.
36. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
37. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBL J 2000; 19: 1290-1300.
38. Rios M, Fan G, Fekete C et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 2001; 15: 1748-1757.
39. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M. Selective deletion of BDNF in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 2007; 27: 14265-14274.
40. Cordeira JW, Frank L, Sena-Esteves M, Pothos EN, Rios M. Brain-derived neurotrophic factor regulates hedonic feeding by acting on the mesolimbic system. J Neurosci 2010; 30: 2533-2541.
41. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62 (Suppl. 23): 45-66.
42. Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets 2006; 7: 1681-1695.
43. Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL. 759 C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002; 360: 1790-1791.
44. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087.
45. De Luca V, Müller DJ, Hwang R et al. HTRC2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum Psychopharmacol 2007; 22: 463-467.
46. Sicard MN, Zai CC, Tiwari AK et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010; 11: 1561-1571.
47. Tiwari AK, Rodgers JB, Sicard M et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol 2010; 34: 1484-1490.
48. Müller DJ, Zai CC, Sicard M et al. Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2012; 12: 156-164.
49. Tiwari AK, Zai CC, Meltzer HY, Lieberman JA, Müller DJ, Kennedy JL. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol 2010; 25: 253-259.
50. Tiwari AK, Zai CC, Likhodi O et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010; 35: 1315-1324.
51. Sickert L, Müller DJ, Tiwari AK et al. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European Americans. Pharmacogenomics 2009; 10: 1169-1176.
52. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JV, Reynolds GP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008; 192: 424-428.
53. Zai G, Müller DJ, Volavka J et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology 2006; 188: 171-182.
54. Xu B, Goulding EH, Zang K et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003; 6: 736-742.
55. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984-994.
56. Burghardt KJ, Gardner KN, Johnson JW, Ellingrod VL. Fatty acid desaturase gene polymorphisms and metabolic measures in schizophrenia and bipolar patients taking antipsychotics. Cardiovasc Psychiatry Neurol 2013: 596945. doi: 10.1155/2013/596945.
57. Chang HH, Gean PW, Chou CH et al. C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients. J Clin Psychopharmacol 2010; 30: 512-517.